INTRODUCTION

Gastric cancer (GC) has become a continuous and major global health problem, and GC was the fifth most frequent cause of cancer-related death in 2020.¹ The latest statistics from the Chinese National Cancer Center showed that the incidence rate of GC ranks second² among malignant tumors, largely due to high rates of Helicobacter pylori infection.³ In particular, most GC patients are diagnosed in
the middle or advanced stages and receive a dismal prognosis. Therefore, discovering new biomarkers at the molecular level for early diagnosis, tumor grading, and prognosis of GC is a critical need.

Long noncoding RNAs (lncRNAs), a class of functional noncoding RNA transcripts >200 nt in length, are key regulators of GC occurrence, development, metastasis, and GC cell escape from the immune system. IncRNAs can regulate gene expression by regulating epigenetic modifications, transcription, and posttranscriptional events. The association between IncRNAs and GC development has been established based on multiple studies. For example, the lncRNA HNF1A-AS1 promotes GC cell proliferation and cell cycle progression by enhancing the expression of cell cycle regulators and promoting p21 ubiquitination-mediated degradation. In addition, under metabolic stress, MACC1-AS1 enhances GC cell glycolysis and antioxidant activity through increased AMPK/Lin28-mediated MACC1 mRNA stability. Most studies have focused on lncRNAs that play roles in promoting GC progression. But IncRNAs that function as a tumor suppressor also play an important role in GC. Thus, we focused on the lncRNAs that play a tumor suppressor role in GC.

The N6-methyladenosine (m6A) methylation modification is the most common IncRNA modification and acts as a critical upstream regulatory mechanism of lncRNAs. In cancers, a m6A methyltransferase catalyzes the methylation of oncogene/suppressor RNA, and then a series of m6A reader proteins recognize these m6A modifications, leading to upregulated or downregulated oncogene/suppressor gene expression. m6A modification is highly prevalent in GC, and its dynamic regulation has been shown to be significantly correlated with gene expression. ARHGAP5-AS1 stimulates the m6A modification of ARHGAP5 in the cytoplasm by recruiting METTL3 to promote GC progression. ALKBH5 promotes GC cell invasion and metastasis by demethylating the lncRNA NEAT1. Thus, m6A-mediated regulation might greatly influence GC progression.

In this study, we reveal that TP53TG1 inhibits the progression of GC by interacting with cancerous inhibitor of protein phosphatase 2A (CIP2A) and triggering its ubiquitination-mediated degradation. In addition, we explored a new mechanism of TP53TG1 downregulation mediated by m6A modification in GC. The results demonstrate that TP53TG1 is a tumor suppressor, which may serve as a crucial marker of GC prognosis and may be a promising therapeutic target.

2 | MATERIALS AND METHODS

2.1 | Tissue samples

A total of 82 matched normal and cancer tissues were collected from 82 patients with GC who were diagnosed at the First Affiliated Hospital of Sun Yat-sen University and underwent radical excision between January 2012 and December 2017. Patients who died within 3 months after surgery or had more than one primary tumor were excluded. None of the patients had received preoperative chemotherapy or radiotherapy. All tissue specimens were separated and frozen at ~80°C or formalin fixed and paraffin embedded. Experienced pathologists from the First Affiliated Hospital of Sun Yat-sen University reviewed the tissue sections. Written and informed consent was obtained from all patients. The study followed the guidelines of the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University.

2.2 | Immunohistochemistry (IHC)

Sample slides were deparaffinized, rehydrated, and subjected to antigen retrieval; endogenous peroxidase activities were blocked. Slides were then incubated at 4°C overnight in the indicated antibodies, including those against CIP2A (1:200; ab99518, Abcam), PP2A (1:200; Merck), Ki67 (1:200; 12202S, CST), and BAX (1:200; 5023S, CST). Then, the slides were incubated with a horseradish peroxidase-conjugated secondary antibody and DAB and counterstained with hematoxylin. Images were obtained with confocal laser scanning microscope (Zeiss) and processed using the ZEN imaging software. IHC scoring of tissue sections was performed as described previously.

2.3 | Cell culture

The GC cell lines AGS, MKN28, BGC823, HCG27, MGC803, and MKN45 were derived from the Type Culture Collection of the Chinese Academy of Sciences. The normal gastric epithelial cell lineGES-1 was obtained from the Lab Animal Center of the Fourth Military Medical University. MKN28, HCG27, MGC803, and MKN45 were cultured in DMEM (Invitrogen), BGC823 was cultured in RPMI-1640 (Invitrogen), and AGS was cultured in F12 (Invitrogen). All cell lines were supplemented with 10% fetal bovine serum (GIBCO) in an incubator with 5% CO2 and 95% room air at 37°C. The cell lines were tested for potential mycoplasma contamination by PCR using a MycoGuardTM Mycoplasma PCR detection kit (GeneCopoeia) and were confirmed mycoplasma negative.

2.4 | Lentivirus construction and cell transfection

Packaging vectors pSPAX2 and pMD2.G0 were, respectively, cotransfected with overexpression or knockdown of stable transfection vector plasmids into HEK293T cells using Lipofectamine 3000 (Invitrogen). After 16 hours of transfection, the medium of HEK293T cells was removed and replaced with fresh culture medium. After 48 hours, the cell supernatant was filtered and collected with 0.22-micron filter membrane. Then, the GC cell lines were infected with the corresponding recombinant lentivirus for 48 hours and subsequently selected with 2 μg/ml puromycin for 2 weeks. TP53TG1 gene, ALKBH5 gene, and CIP2A gene were cloned into the pEZ-Lv201 lentivirus vector (GeneCopoeia), while the corresponding vector pEZ-Lv201 (EGFP, a reporter gene) was used as a control vector.
Lentiviral shRNA constructs were obtained from GeneCopoeia (GeneCopoeia). The lentiviral shRNA control plasmid was added with a scrambled control sequence (ACAGAAGCGATTTGATC), which was basically mismatched. The targeting sequences were as follows: Lv201-shTP53TG1#1 GCATCAGCTGATGAGACGC, Lv201-shTP53TG1#2 GCAGGAAGCGATTTAAGAC; Lv201-shALKBH5#1 GAAAGGCTGTTGGCATCAATA, Lv201-shALKBH5#2 CCTCAGGAAGACAGATTAGA.

2.5 | Immunofluorescence in situ hybridization (FISH)
Cy3-labeled TP53TG1 probe was designed and synthesized by the GenePharma Fluorescent in Situ Hybridization Kit (GenePharma). For FISH assay, AGS or MKN28 cells (3 × 10^5 cells) were fixed in 4% formaldehyde and permeabilized with 0.3% Triton X-100 for 15 minutes and washed three times with PBS and once in 2× SSC buffer. Hybridization was carried out using Cy3-labeled TP53TG1 probe sets at 37°C for 16 hours. Images were obtained with a confocal laser scanning microscope (Zeiss) and processed using the ZEN imaging software. TP53TG1 probes are listed in Table S1.

2.6 | Reverse-transcription quantitative PCR (RTqPCR)
An RNA isolation plus kit (TaKaRa) was used to extract total RNA from GC tissues or cells. After reverse transcription with Primer ScriptTM RT Reagent (TaKaRa), cDNAs were harvested and then subjected to real-time PCR analysis with a SYBR green detection system (Applied Biosystems); the amplification cycle of qualitative RT-PCR was 35. GAPDH was used as the endogenous control. The primers used for the qPCR analysis are listed in Table S1.

2.7 | Chromatin isolation by RNA purification
We designed the probes for CHIRP (one probe per 100 nt of RNA). The probes were biotin-labeled DNA probes that were complementary to the target RNA sequence. TP53TG1 probes used for CHIRP are listed in Table S1. RNA was extracted from AGS cells or transcribed in vitro and purified. Then, the purified RNA was pre-immunoprecipitated with specific prewashed beads at 37°C for 30 minutes. After centrifugation, the supernatant was retained. Subsequently, the supernatant was hybridized with denatured biotin-labeled RNA probes at 55°C for 2 hours. Next, the prewashed beads were added, rotated at 37°C for 1 hour, and centrifuged at 3000g for 30 seconds. The supernatant was discarded, and the beads were washed five to six times. Separation buffer was used to elute RNA and protein sequentially. Then, the protein from the complex was subjected to immunoblot assay and liquid chromatography (LC)/mass spectrometry (MS) assay, and the RNA complexes were purified with TRizol reagent and then subjected to RT-qPCR analysis.

2.8 | RNA immunoprecipitation (RIP)
RNA immunoprecipitation assays were carried out using a Magna RIP RNA-binding protein immunoprecipitation kit (Millipore) according to the manufacturer's instructions. Anti-CIP2A (Abcam) and normal rabbit IgG (CST) were used to immunoprecipitate target RNA or as the negative control. Finally, RT-qPCR analysis was performed to detect the enrichment of the coprecipitated RNA binding to CIP2A.

2.9 | Western blotting analysis
Total proteins were extracted using RIPA supplemented with protease and phosphatase inhibitor reagents (Thermo-Fisher Scientific). Equal amounts of protein samples were separated by SDS/PAGE and then transferred to PVDF membranes (Millipore). Next, the membranes were probed with specific primary antibodies at 4°C overnight (Table S2). After incubating with the secondary antibody, Immunoreactive bands were visualized with enhanced chemiluminescence reagents (Bio-Rad).

2.10 | In vivo assays
Firstly, Lv201-TP53TG1 or control vector was stably transfected into BGC823 cells. Then, nude mice were injected in the axilla with 100μl (5 × 10^7 cells/ml) of the cell suspension containing the overexpression group or the NC group cells. The length and diameter of the subcutaneous tumors were measured and recorded, and their growth curves were drawn. Four and a half weeks after the tumor cell inoculation, the nude mice were sacrificed by cervical dislocation. The subcutaneous tumor was removed, measured, weighed, and photographed. Specimens were fixed with formalin solution and then sectioned and stained. In the lung metastasis model, 100μl (1 × 10^7 cells/ml) of the suspension with control or TP53TG1-overexpressing BGC823 cells was injected into the tail vein. After sacrifice, the lung specimens were separated and photographed, and the measurements were recorded. The lung specimens were fixed with formalin solution, sliced, and stained with HE; then, the number of metastatic nodules in each field of view was counted.

2.11 | Methylated RIP
Cells in 150-mm dishes were crosslinked by UV (4000 × 100 μJ/cm², twice; Spectronics) and collected in PBS. The RNA-m6A complexes were isolated using 500μl of MeRIP buffer (150mM NaCl, 10mM Tris–HCl, pH7.5; and 0.1% NP-40) and centrifuged at 21,000g for 5 minutes at 4°C. Then, the supernatant was collected in other
enzyme-free tubes, added to 5 μg anti-m6A (Synaptic System) or anti-IgG (Proteintech), and incubated overnight at 4°C. Incubated lysates containing antibody-protein-RNA complex with protein A/G magnetic beads (Thermo Fisher Scientific) were rotated for 1 hour at 4°C. Subsequently, the beads were collected and washed twice with wash buffer (0.1% SDS and 0.5% NP-40 in PBS). The RNA-m6A complex was de-crosslinked by heating at 45°C for 1 hour. Finally, the beads were extracted from cells using TRIzol (Thermo-Fisher) for RNA isolation, and RT-qPCR analysis was performed to detect the enrichment.

2.12 | RNA stability

For RNA stability measurements, GC cells were administered actinomycin D (Act-D, 5 μg/ml). After incubation, the cells were collected at the indicated times (0, 2, 4, 6, 8, or 16 hours). RNA was extracted using TRIzol reagent, and reverse-transcription was performed to detect the remaining mRNA using RT-qPCR.

2.13 | Statistical analysis

All data are presented as the mean ± standard deviation. Appropriate statistical methods including Student's t test, Wilcoxon signed-rank test, Mann-Whitney test, and Pearson chi-square test were used to calculate differences between groups. P values <0.05 indicate statistical significance. Statistical analyses were performed using SPSS Statistics software (version 18.0) or GraphPad Prism 8 software.

3 | RESULTS

3.1 | TP53TG1 is downregulated in GC and inversely associated with patient prognosis

To investigate the role of IncRNAs in GC, we first examined IncRNA expression profiles in three GC tissue samples and adjacent normal tissues by RNA sequencing. Among the differentially expressed IncRNAs, 82 were significantly upregulated, while 136 were significantly downregulated in GC tissues compared with the noncancerous tissues (fold change >2, p <0.05, Figure S1A). Among them, TP53TG1 was the most significantly downregulated IncRNA in GC tissues compared with normal tissues (Figure 1A). By using an independent panel of 82 GC tissues and adjacent normal tissues, we found that TP53TG1 expression was downregulated in GC (Figure 1B), which was also confirmed by agarose gel electrophoresis assays (Figure 1C). More importantly, low TP53TG1 expression was associated with more advanced clinical features such as tumor diameter, differentiation, TNM categories, and lymph node metastasis stage. We also found that lower TP53TG1 expression was significantly correlated with worse prognosis in GC patients (Figure 1D, Table 1). The Kaplan-Meier plotter (http://www.kmplot.com/) was used to assess the correlation between TP53TG1 and GC patients’ survival, and the results further confirmed the above finding (Figure 1E). These results suggest that TP53TG1 can be used as a potential index for the early diagnosis and prognosis of GC. In addition, RT-qPCR revealed significantly lower levels of TP53TG1 expression in GC cells (Figure 1F). To investigate the cellular location of TP53TG1, RT-qPCR of the nuclear and cytoplasmatic fractions of GC cells was conducted, which revealed that TP53TG1 was mainly localized in the cytoplasm (Figure 1G). FISH assay further confirmed that TP53TG1 located primarily in the cytoplasm in GC cells (Figure 1H).

3.2 | TP53TG1 functions as a tumor suppressor in vitro

To determine the physiological role of TP53TG1 in cancer, we stably overexpressed TP53TG1 in MKN28 and BGC823 cells and knocked it down in AGS cells (Figure 2A). With CCK-8, EdU assays, and colony formation, we found that ectopic expression of TP53TG1 inhibited MKN28 and BGC823 cell proliferation, while knockdown of TP53TG1 promoted the proliferation of AGS cells (Figure 2B–D, Figure S2A–C). Overexpression of TP53TG1 reproducibly resulted in cell cycle redistribution with a significant increase in the number of synchronized MKN28 and BGC823 cells in the G0/G1 phase and a significant decrease in these cells in other cell cycle stages. Moreover, depletion of TP53TG1 promoted cell cycle progression (Figure 2E, Figure S2D,F).

We found that TP53TG1 overexpression induced higher early apoptosis and late apoptosis rates, as measured by annexin-V and propidium iodide (PI) staining, whereas depletion of TP53TG1 decreased the apoptosis rate of AGS cells (Figure 2F, Figure S2E,G). Importantly, we observed that TP53TG1 attenuated GC cell migration and invasion (Figure 2G,H, Figure S2H,I). The epithelial-mesenchymal transition (EMT) process is one of the major causes of cell invasion and migration.19 We then detected key EMT markers and found that N-cadherin, Vimentin, and Slug were all downregulated, while E-cadherin was upregulated when TP53TG1 was overexpressed. Knockdown of TP53TG1 significantly promoted EMT by leading to an opposite change of these markers (Figure 2I, Figure S3A,B). Together, our results demonstrate that TP53TG1 is involved in tumor progression, specifically suggesting that TP53TG1 performs a critical tumor-suppressing function in GC progression.

To explore the downstream signaling pathways in which TP53TG1 is involved, we performed mRNA sequencing and subsequent bioinformatic analysis with MKN28 cells treated with an empty vector or TP53TG1 overexpression vector. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that TP53TG1 was correlated with PI3K/AKT pathways directly involved in the regulation of the cell cycle, apoptosis, and cell migration (Figure S1B,C). By analyzing the activities of the PI3K/AKT pathway in GC cells, we found that TP53TG1 overexpression reduced AKT Thr308 and Ser473 phosphorylation, while TP53TG1 knockdown increased phosphorylation at these sites (Figure 2J).
To investigate the potential mechanism underlying the biological functions of TP53TG1, we designed and synthesized specific TP53TG1 probes to perform CHIRP assay and subsequent MS analysis (Figure 3A). The MS results showed that the key cancer-promoting protein CIP2A has a high abundance (Figure S1D). CIP2A is reported to be an upstream inhibitor of the PI3K/AKT signaling pathway by inhibiting PP2A activity. To further confirm the
interaction between TP53TG1 and CIP2A, we carried out Western blot analysis with CHIRP assay and found that the CIP2A was pulled down by TP53TG1 (Figure 3B). Furthermore, we conducted RIP experiment and discovered that compared with the IgG control, the anti-CIP2A antibody bound with higher abundance to TP53TG1 in GC cells (Figure 3C). These findings indicated a direct binding between TP53TG1 and CIP2A. We further analyzed the expression of CIP2A when the TP53TG1 level was changed and found that the protein level of CIP2A was significantly reduced when TP53TG1 was overexpressed (Figure 3D), while it was significantly increased when TP53TG1 was knocked down (Figure S2J). In addition, IF staining showed lower levels of the CIP2A protein in TP53TG1-overexpressing GC cells than in control cells (Figure 3E), while higher levels of the CIP2A protein were observed in TP53TG1-knockdown AGS cells than in control cells (Figure S2K). However, we found no difference in the mRNA level of CIP2A when TP53TG1 was changed (Figure 3F). In addition, IHC staining combined with RT-qPCR analysis also revealed downregulated CIP2A expression in tissue samples with high TP53TG1 expression (Figure 3G).

According to these findings, we inferred that the stability of the CIP2A protein was diminished upon binding to TP53TG1, which meant that TP53TG1 promoted its degradation. Therefore, we conducted time-varying gradient stimulation experiments with the protein synthesis inhibitor imine cyclohexanone (CHX) and proteasome inhibitor (MG132) and found that when TP53TG1 was overexpressed, the CIP2A protein level decreased significantly, indicating that TP53TG1 promoted the degradation of the CIP2A protein (Figure 3H–J). Subsequent ubiquitination assays revealed that TP53TG1 overexpression increased the level of ubiquitinated CIP2A protein in MKN28 and BGC823 cells (Figure 3K). Taken together, we concluded that TP53TG1 can directly bind to CIP2A and promote its degradation.

TABLE 1 Relationships between TP53TG1 expression and clinical pathological gastric cancer (GC) parameters

| Parameters                      | Number of cases | TP53TG1 expression | P value |
|---------------------------------|-----------------|--------------------|---------|
|                                 |                 | Low (43)           | High (39) |      |
| Sex                             |                 |                    |         |      |
| Male                            | 55              | 26                 | 29      | 0.18117 |
| Female                          | 27              | 17                 | 10      |         |
| Age                             |                 |                    |         |      |
| <60                             | 40              | 22                 | 18      | 0.65071 |
| ≥60                             | 42              | 21                 | 21      |         |
| Tumor size                      |                 |                    |         |      |
| ≤4 cm                           | 42              | 14                 | 28      | 0.00039*** |
| >4 cm                           | 40              | 29                 | 11      |         |
| Primary tumor (T) stage         |                 |                    |         |      |
| T1-T2                           | 29              | 7                  | 21      | 0.00034*** |
| T3-T4                           | 54              | 36                 | 18      |         |
| Lymph node metastasis           |                 |                    |         |      |
| Yes                             | 58              | 35                 | 23      | 0.02585** |
| No                              | 24              | 8                  | 16      |         |
| Distant metastasis              |                 |                    |         |      |
| Yes                             | 22              | 17                 | 5       | 0.0064** |
| No                              | 60              | 26                 | 34      |         |
| TNM stage                       |                 |                    |         |      |
| I/II                            | 34              | 11                 | 23      | 0.0022** |
| III/IV                          | 48              | 32                 | 16      |         |

The pathological diagnoses and classifications were made according to Ref.44
**p < 0.01; ***p < 0.001.
3.4 CIP2A is associated with poor survival and can partially reverse the inhibitory effects of TP53TG1 in GC

We assessed CIP2A protein expression in 82 pairs of matched GC cancer tissues and normal tissues from the First Affiliated Hospital of Sun Yat-sen University. We found that CIP2A protein expression was elevated in cancer tissues (Figure 4A,B) and that high CIP2A expression correlated with significantly worse overall survival (Figure 4C). We also found that CIP2A protein expression was elevated in cancer tissues compared with normal gastric tissues in Human Protein Atlas data and was associated with poor prognosis (Figure S4A,B).

To determine whether CIP2A plays a crucial role in the TP53TG1-mediated regulation of GC growth and metastasis, proliferation and invasion abilities were examined in GC cells overexpressing CIP2A and TP53TG1. CCK-8 and colony formation assays showed that the TP53TG1-induced suppression of GC cell proliferation was partially reversed when CIP2A expression was increased (Figure 4D,E and Figure S4C,D). Transwell assays revealed that TP53TG1-mediated suppression of cell migration and invasion was partially reversed in cells cotransfected with TP53TG1 and CIP2A (Figure 4F,G). In addition, concomitant overexpression of TP53TG1 and CIP2A partially counteracted the effects of TP53TG1 on AKT Thr308 and Ser473 phosphorylation in MKN28 and BGC823 cells (Figure 4H). Based on these results, CIP2A is responsible for TP53TG1-mediated GC cell growth and progression.

3.5 TP53TG1 suppresses the progression of GC by attenuating the PI3K/AKT pathway

The PI3K/AKT pathway has been reported to participate in cell proliferation, cell migration and cancer metastasis. As TP53TG1 mediates tumor suppressor activity by attenuating PI3K/AKT, we performed rescue assays to further prove it. The AKT inhibitor MK2206 greatly inhibited TP53TG1 knockdown-induced GC cell growth, as shown by CCK-8 and colony formation assays (Figure 5A-C). Meanwhile, we observed that MK2206 also suppressed the migration and invasion of TP53TG1 knockdown-induced cells (Figure 5D,E). In addition, Western blotting showed that MK2206 inhibited AKT Thr308 and Ser473 phosphorylation (Figure 5F). Altogether, these data show that the PI3K/AKT pathway is essential for mediating TP53TG1 tumor-inhibiting activity.

3.6 TP53TG1 suppresses the progression of GC in vivo

To further study the roles of TP53TG1 in vivo, we established subcutaneous tumor and lung metastasis models in nude mice (Figure 6A). Compared with that in the control group, the tumor growth rate was decreased in the TP53TG1-overexpressing group. Tumor weight and volume were also significantly reduced in the TP53TG1-overexpressing group (Figure 6B,C). Hematoxylin and eosin (HE) staining was performed to identify tumors (Figure 6D left panel). More importantly, the expression of Ki67, CIP2A, and BAX was negatively correlated with the TP53TG1 level in these tumor tissues, while PP2A expression was positively associated with the TP53TG1 level (Figure 6D). TUNEL apoptosis assay with xenograft tumor samples revealed that TP53TG1 facilitated the apoptosis of GC cells in vivo (Figure 6D right panel). These results suggested a potential inhibitory effect of the TP53TG1 on the proliferation of GC cells in vivo. Furthermore, by injecting stably transfected GC cells into the tail vein of nude mice, TP53TG1 dramatically inhibited the development of pulmonary metastasis (Figure 6E,F).

3.7 ALKBH5 regulates TP53TG1 stability through m6A modification

Recent advancements in understanding tumor epigenetic regulation have shed light on the involvement of the m6A modification in lncRNA functions. According to the online bioinformatics database m6Avar, there are five RRACU m6A sequence motifs in the exon region of TP53TG1 (on chr7 at 87341611(−), 87341669(−), 87345112(−), 87345112(−), and 87345247(−)). We then speculated whether m6A was associated with TP53TG1 downregulation in GC cells. Compared with the normal GC cell line GES-1, the m6A level of TP53TG1 was lower in MKN28, BGC823, HGC27, MGC803, MKN45, and AGS cells, indicating that m6A may be involved in TP53TG1 downregulation (Figure 7A). The sequence motifs in m6A peaks were identified with the MEME Suite (https://meme-suite.org/meme/) (Figure 7B).

ALKBH5 is a crucial m6A methyltransferase and has been reported to be involved in GC development. ALKBH5 has been previously found to be elevated in the cancer tissues of patients and play pro-oncogenic roles. RT-qPCR results indicated that the ALKBH5 expression level was negatively correlated with the level of TP53TG1 in the 82 GC tissue samples (Figure S5A). To explore the effects of ALKBH5 on TP53TG1 stability in GC cells, we...
FIGURE 4 CIP2A partially reversed the tumor inhibitory function of TP53TG1 in gastric cancer (GC) cells. (A) Representative image of CIP2A immunohistochemistry (IHC) staining showing 82 matched normal and GC tissues. (B) IHC score shows the expression of CIP2A in matched normal and GC tissues. (C) Kaplan-Meier analysis revealed that high CIP2A expression in GC patients was significantly correlated with a dismal prognosis. Median histochemical value of CIP2A value (5.6) was used to divide patients into CIP2A-high and CIP2A-low groups. (D) CIP2A reversed the inhibitory effects of TP53TG1 on the proliferation of GC cells, as assessed by CCK-8 assay. (E) CIP2A reversed the inhibitory effects of TP53TG1 on the colony formation of GC cells. (F) Transwell assays showing that the TP53TG1-mediated inhibition of migration and invasion was rescued by CIP2A in GC cells. (G) Statistical analysis of the migration and invasion assays is shown. (H) Western blotting showing that the TP53TG1-mediated inhibition of the PI3K/AKT signaling pathway was rescued by CIP2A in GC cells.

FIGURE 5 TP53TG1 suppressed the progression of gastric cancer (GC) by attenuating the PI3K/AKT pathway. (A-C) Proliferation assays of the knockdown-induced AGS cells treated with DMSO or an AKT inhibitor MK2206. (D-E) Transwell assays of the knockdown-induced AGS cells treated with DMSO or AKT inhibitor MK2206. (F) Western blotting detecting the protein levels of the PI3K/AKT pathway on the knockdown-induced AGS cells treated with DMSO or AKT inhibitor MK2206.
stably knocked down ALKBH5 with a lentivirus vector in MKN28 and BGC823 cell lines. Western blotting assays and RT-qPCR verified the knockdown efficiency (Figure 7C,D). Compared with that in the control group, the m6A level of TP53TG1 was higher in ALKBH5-silenced GC cells (Figure 7E,F). Besides, we found that ALKBH5 silencing was associated with upregulated TP53TG1 expression (Figure 7G). RIP analysis demonstrated that TP53TG1 was significantly enriched by the ALKBH5 antibody in both MKN28 and BGC823 cell lines (Figure 7H). We then treated GC cells with actinomycin D to block transcription and found that
silencing significantly increased the half-life of TP53TG1 in MKN28 and BGC823 cells (Figure 7J). We also overexpressed ALKBH5 with a lentivirus vector in AGS cells (Figure S5B,C). We found that ALKBH5 overexpression dramatically decreased m6A modification level of TP53TG1 in GC cells (Figure S5D). In addition, we found that ALKBH5 overexpression was associated with decreased TP53TG1 expression (Figure S5E). TP53TG1 was also significantly enriched in the anti-ALKBH5 group in the AGS cell line according to the RIP analysis (Figure S5F). We also found that ALKBH5 overexpression significantly decreased the half-life of TP53TG1 in the AGS cell line by using actinomycin D to block its transcription (Figure S5G). These results suggested that ALKBH5-mediated m6A is associated with the downregulation of TP53TG1 in GC cells, probably by regulating TP53TG1 transcript stability.
4 | DISCUSSION

Long noncoding RNAs are newly discovered players in the cancer paradigm, with regulatory functions in both carcinogenic and tumor suppressive pathways. Recent reports have demonstrated that TP53TG1 exerts oncogenic or tumor-suppressing functions in different cancers. TP53TG1 plays a cancer-promoting effect in pancreatic cancer and glioma, but it exerts an antitumor effect in colorectal cancer, non–small cell lung cancer, and liver cancer. In this study, we found that TP53TG1 expression was significantly downregulated and exerted tumor-suppressing functions in GC.

Previous studies have shown that the mechanism of lncRNAs in human diseases is linked to their cellular location. IncRNAs located in the nucleus mainly interact with chromatin and regulate transcription and RNA processing. The main biological functions of those located in the cytoplasm mainly include the stabilization of mRNAs, participation in the posttranscriptional regulation of mRNAs as competing endogenous RNAs (ceRNAs), and protein modification processes. The aberrant expression of lncRNAs exerts diverse effects on the pathogenesis of cancers through various mechanisms. In pancreatic cancer, TP53TG1 promotes the growth and progression of pancreatic ductal carcinoma by competitively binding to miR-96 and regulating the KRAS expression, while in non–small cell lung cancer, TP53TG1 increases the sensitivity to cisplatin by regulating the miR-18a/PTEN axis. Cytoplasmic lncRNAs also can affect the expression, activity, and/or cell location of proteins by binding to them. In liver cancer, TP53TG1 affects the WNT/β-catenin signaling pathway by binding to PRDX4. The epigenetic inactivation of TP53TG1 abates the transcriptional suppression of YBX1-targeted growth-promoting genes, and contributes to the generation of chemoresistance in gastrointestinal cancer. Furthermore, TP53TG1 under glucose deprivation may promote cell proliferation and migration by influencing the expression of glucose metabolism–related genes in glioma. Herein, our results indicated that TP53TG1 binds to CIP2A and regulates its subsequent ubiquitin-mediated degradation, thus inhibiting the activation of the PI3K/AKT pathway. CIP2A is a human oncoprotein that can promote cancer cell proliferation, anchorage-independent cell growth, and resistance to apoptosis. The PI3K/Akt signaling pathway is activated in an extensive variety of tumor types and drives cancer cell proliferation and survival. The CIP2A complex inhibits PP2A activity to regulate the AKT pathway by dephosphorylating both the Thr308 and Ser 473 residues in Akt in a context-dependent manner. In this study, we found that CIP2A overexpression can partially reverse the inhibition of the PI3K/AKT pathway induced by TP53TG1, enhancing AKT phosphorylation/activation in GC cells.

TP53TG1 is an important tumor suppressor in cancer, but the reason for its decreased expression is not clear. Diaz-Lagares A et al demonstrated that the low expression of TP53TG1 may be related to DNA methylation and the regulation of TP53 transcription at the DNA level. In recent years, m6A modification has been shown to have significant effects in regulating all stages of the RNA life cycle. The abnormality of the enzyme or reading protein that regulates m6A methylation modification will lead to the occurrence of many diseases. For cancers, m6A methyltransferase catalyzes the methylation of oncogene/suppressor RNA, and then a series of m6A reading proteins recognize these m6A methylation modifications, and upregulate or downregulate the oncogene/suppressor gene expression, playing a corresponding role in promoting or suppressing cancer. ALKBH5 has been shown to interact with SOX2, causing SOX2 mRNA demethylation, and resulting in increased SOX2 expression. Here, we analyzed data from a bioinformatics database and MeRIP experiment results and found that m6A modification was enriched on TP53TG1 in GC cells. In addition, ALKBH5 negatively regulated the m6A modification of TP53TG1, thereby affecting the stability of its RNA. Thus, our results indicate that the decrease of TP53TG1 in GC may be attributed to m6A modification.

In summary, our study revealed that TP53TG1 binds to CIP2A and promotes its ubiquitination and then inhibits the activation of the PI3K/AKT pathway. We also highlighted that ALKBH5, a m6A recognition molecule, reduces the m6A modification level of TP53TG1, thus affecting the stability of RNA. The above findings provide a potential molecular target for the clinical treatment of GC.

ACKNOWLEDGEMENTS

The authors thank GeneCopoeia(USA) for plasmids construction and Guangzhou Gene Denovo Biotechnology Co.,Ltd(China) for the support of RNA-seq.

FUNDING INFORMATION

This study was supported by the National Natural Science Foundation of China (81871915 and 81672343) and the National Science Foundation of Guangdong, China (2022A1515012140, 2017A030313570, 2018A030313543).

CONFLICT OF INTEREST

The authors have no conflict of interest.

ETHICS STATEMENT

All human samples were obtained with informed consent from patients with gastric cancer. Ethical consent was granted from the Ethical Committee Review Board of the First Affiliated Hospital of Sun Yat-sen University. The animal study was reviewed and approved by the Ethical Committee Review Board of the First Affiliated Hospital of Sun Yat-sen University (permit number: No. [2020]035).

ORCID

Jianbo Xu https://orcid.org/0000-0001-9143-168X

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747-795.

3. Cai Q, Shi P, Yuan Y, et al. Inflammation-associated senescence promotes Helicobacter pylori-induced atrophic gastritis. Cell Mol Gastroenterol Hepatol. 2021;11(3):857-880.

4. Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10.

5. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. 2020;69(4):748-763.

6. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5-18.

7. Statello L, Guo CJ, Chen LL, et al. Inflammation-associated senescence contains tumorigenicity of glioblastoma stem-like cells by sustaining ZFPM2-AS1. Cell Death Dis. 2020;11(5):384.

8. Zhao Y, Liu Y, Lin L, et al. The lncRNA MACC1-AS1 promotes gastric cancer. Cancer Lett. 2020;44(63):662-670.

9. Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21(2):102-117.

10. Romero-Barrios N, Legascue MF, Benhamed M, Ariel F, Crespi M. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21(2):102-117.

11. Liu HT, Liu S, Liu L, et al. Inflammation-associated senescence promotes Helicobacter pylori-induced atrophic gastritis. Cell Mol Gastroenterol Hepatol. 2021;11(3):857-880.

12. Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10.

13. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. 2020;69(4):748-763.

14. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5-18.

15. Statello L, Guo CJ, Chen LL, et al. Inflammation-associated senescence contains tumorigenicity of glioblastoma stem-like cells by sustaining ZFPM2-AS1. Cell Death Dis. 2020;11(5):384.
population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Fang D, Ou X, Sun K, et al. m6A modification–mediated IncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. Cancer Sci. 2022;113:4135-4150. doi: 10.1111/cas.15581